Revista de Senologia y Patologia Mamaria最新文献_第3页

Breast collision tumor: malignant phyllodes tumor and synchronous ductal carcinoma, case report 乳腺碰撞瘤：恶性叶状瘤及同期导管癌1例

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-01-13 DOI: 10.1016/j.senol.2025.100732

Marcelo Chávez Diaz , Daniel Enrique Castro Vela , María del Rosario Cueva Perez

引用次数: 0

Practice of breast self-examination and associated knowledge and attitudes among female students in the Kurdistan region of Northern Iraq: A cross-sectional study 伊拉克北部库尔德斯坦地区女学生乳房自我检查的实践及相关知识和态度：一项横断面研究

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-02-18 DOI: 10.1016/j.senol.2026.100747

Rebwar Rzgar Qadir, Danyar Hamid Mohammed Amin

{"title":"Practice of breast self-examination and associated knowledge and attitudes among female students in the Kurdistan region of Northern Iraq: A cross-sectional study","authors":"Rebwar Rzgar Qadir, Danyar Hamid Mohammed Amin","doi":"10.1016/j.senol.2026.100747","DOIUrl":"10.1016/j.senol.2026.100747","url":null,"abstract":"<div><h3>Objectives</h3><div>Early identification is essential to improving the prognosis and outcomes for breast cancer patients. This study focused on evaluating the practice of breast self-examination (BSE) among female students at the Raparin Technical and Vocational Institute in Sulaymaniyah city, while also assessing their knowledge, attitudes, and perceived barriers to guide curriculum integration and specific educational interventions.</div></div><div><h3>Methodology</h3><div>An institutional-based cross-sectional study was carried out between February 2025 and June 2025 among 226 students at the Raparin Technical & Vocational Institute in Rania City, Sulaymaneyah Province, northern Iraq. Data were collected using Google Forms, and SPSS Statistics Software 27 was used to evaluate it.</div></div><div><h3>Results</h3><div>Students’ mean age was 21.8 years (95% CI: 21.37–22.03). Parents’ educational level varied significantly, with mothers being illiterate in 48.7% of cases. Overall, 57.1% of students demonstrated good knowledge regarding BSE, while 42.9% had poor knowledge. The mean attitude score was 26.25 (SD = 3.91), indicating a generally positive attitude among participants. However, only 40.3% of students reported practicing BSE, whereas 59.7% had never practiced it.</div></div><div><h3>Conclusion</h3><div>Majority of the students had average knowledge, a positive attitude and bad practice in breast self-examination. To address the issue, educational programs that explicitly target breast self-examination behavior are required. More studies are encouraged to address this issue in other amenities and geographical locations throughout the region.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100747"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147398113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of the diagnostic accuracy of contrast-enhanced mammography and MRI 对比增强乳房x线摄影与MRI诊断准确性的比较

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-02-20 DOI: 10.1016/j.senol.2026.100748

Miguel Barrio-Piqueras , Patricia Malmierca , César Urtasun-Iriarte , Carmen Mbongo-Habimana , Manuel de la Torre Carretero , Arlette Elizalde , Luis Javier Pina

{"title":"Comparison of the diagnostic accuracy of contrast-enhanced mammography and MRI","authors":"Miguel Barrio-Piqueras , Patricia Malmierca , César Urtasun-Iriarte , Carmen Mbongo-Habimana , Manuel de la Torre Carretero , Arlette Elizalde , Luis Javier Pina","doi":"10.1016/j.senol.2026.100748","DOIUrl":"10.1016/j.senol.2026.100748","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Contrast-Enhanced Mammography (CEM) and to determine which better estimates lesion size.</div></div><div><h3>Material and methods</h3><div>Between September 2017 and November 2023, 139 histopathologically confirmed lesions from 95 patients who underwent MRI and CEM were retrospectively analyzed. BI-RADS categories and lesion diameters were reassessed. Sensitivity, specificity, and area under the curve (AUC) were calculated. Breast density, background parenchymal enhancement, and discrepancies in lesion size compared to histopathology were evaluated.</div></div><div><h3>Results</h3><div>Among 139 lesions (117 malignant, 22 benign), MRI detected 112 true positives (TPs) and 5 false negatives (FNs); CEM reported 98 TPs and 19 FNs. For benign lesions, MRI showed 8 false positives (FPs) and 14 true negatives (TNs); CEM, 2 FPs and 20 TNs. Sensitivity was 95.7% for MRI vs. 83.8% for CEM (<em>p</em> = 0.002); specificity was 63.6% vs. 90.9%, respectively (<em>p</em> = 0.058). AUC was 0.90 for MRI and 0.86 for CEM (<em>p</em> = 0.45). Both techniques tended to overestimate tumor size (+3.35 mm MRI, +4.04 mm CEM), with no significant difference in accuracy (<em>p</em> = 0.389).</div></div><div><h3>Conclusion</h3><div>MRI showed higher sensitivity than CEM for detecting malignant lesions, although their accuracy was similar. Both techniques tend to overestimate tumor size.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100748"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147398114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological evolution of radioguided surgery as a function of clinical demands in breast cancer 乳腺癌放射引导手术的方法学发展与临床需求

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-02-24 DOI: 10.1016/j.senol.2026.100754

Renato A. Valdés Olmos , Sergi Vidal-Sicart

{"title":"Methodological evolution of radioguided surgery as a function of clinical demands in breast cancer","authors":"Renato A. Valdés Olmos , Sergi Vidal-Sicart","doi":"10.1016/j.senol.2026.100754","DOIUrl":"10.1016/j.senol.2026.100754","url":null,"abstract":"<div><div>Since its incorporation into the sentinel node (SN) procedure more than three decades ago, nuclear medicine has significantly contributed to precision surgery in breast cancer. This contribution has parallelly evolved to the various clinical demands, playing an important role in the current process of surgical de-escalation for both resection of primary tumors and the approach to the axilla. With original indication for cT1–2 tumors without evidence of axillary metastases (N0), it was the radioguided modality of SN biopsy that achieved the highest rates of diagnostic efficacy and reliability. This made it possible to incorporate other clinical categories into the procedure, reaching patients receiving neoadjuvant systemic therapy (NST). In recent years, radioguided surgery (RGS) has also been extended to the management of patients with N+ axilla through implanting radioactive iodine seeds in metastatic lymph nodes, facilitating radioguided biopsy at the end of neoadjuvant therapy. As for non-palpable primary tumors, RGS currently allows their resection either by intralesional injection of radiocolloids or by implantation of radioactive iodine seeds. To address clinical challenges, the practice of RGS has been homogenized by various scientific associations on issues such as radiotracers to be used, site of injection in the breast, standardization of preoperative images, use of intraoperative devices, and synchronization with NST, as well as the management of metastases in non-axillary SN. Recently, new specific radiotracers are making it possible to extend RGS to the resection of distant oligometastases.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100754"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147398107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanorobots for the treatment of breast cancer: Exploration and advancement 纳米机器人治疗乳腺癌：探索与进展

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-01-14 DOI: 10.1016/j.senol.2025.100719

Deepak Kumar , Rishabha Malviya , Sathvik Belagodu Sridhar

{"title":"Nanorobots for the treatment of breast cancer: Exploration and advancement","authors":"Deepak Kumar , Rishabha Malviya , Sathvik Belagodu Sridhar","doi":"10.1016/j.senol.2025.100719","DOIUrl":"10.1016/j.senol.2025.100719","url":null,"abstract":"<div><div>Nanorobots provide a breakthrough in breast cancer treatment, using nanotechnology to identify, target, and treat tumors with unheard-of accuracy. Designed to navigate challenging biological parameters, these tiny devices deliver therapeutic medications directly to tumor sites, thereby reducing systemic toxicity and adverse effects. Nanorobots present a viable substitute for traditional treatments by including cutting-edge technologies such as targeted delivery, biocompatibility, and multifunctionality. This study aims to explore the potential of nanorobots in the treatment of breast cancer. Nanorobots offer precision-based options for breast cancer care by delivering drugs, targeting tumors, and performing diagnostic tests. For instance, DNA nanorobots are designed to recognize signals unique to a tumor and release thrombin or chemotherapy to cut off the blood supply of the tumor. Nanorobots with magnetic and enzyme propulsion improve mobility and can effectively enter tumor microenvironments. Natural homing processes are used in bio-hybrid models, which are generated from live cells, to enhance tumor targeting. Biocompatibility, operational stability, and manufacturing scalability are still issues despite these developments. Even while current propulsion technologies are inventive, they frequently have trouble navigating biological settings that are viscous. Refinement of materials, propulsion methods, and targeting tactics are necessary to overcome these obstacles and improve clinical application in the future. Nanorobots can transform the treatment of breast cancer by providing personalized, effective, and minimally invasive therapeutic alternatives. To fully realize their potential in clinical applications, current biocompatibility and technological issues must be resolved.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100719"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theragnosis in breast cancer: integrating molecular imaging and targeted therapy in the era of personalised medicine 乳腺癌的诊断：在个体化医疗时代整合分子成像和靶向治疗

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-02-26 DOI: 10.1016/j.senol.2026.100756

Macarena Rodríguez-Fraile , Mercedes Mitjavila Casanovas

引用次数: 0

Primary melanoma of mammary skin 原发性乳腺皮肤黑色素瘤

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-02-19 DOI: 10.1016/j.senol.2026.100744

José Richard Tenazoa-Villalobos , Edgar Fermín Yan-Quiroz , Olga Mercedes Viviana Burgos-García , Gladys Llerena-Cobián

引用次数: 0

Exploring the expression of cancer stem cell marker – Aldehyde dehydrogenase isoenzyme 1A1 (ALDH1A1) in various molecular subtypes of breast cancer 探讨肿瘤干细胞标志物乙醛脱氢酶同工酶1A1 （ALDH1A1）在乳腺癌不同分子亚型中的表达

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-02-03 DOI: 10.1016/j.senol.2025.100729

Ramya Suresh , Krishnappa Amita , Kalappa Prashantha , Hamse Kameshwar Vivek , Geethanjali Anil Kumar Burbure , Kanakapura Paramesh Hrushikesh

{"title":"Exploring the expression of cancer stem cell marker – Aldehyde dehydrogenase isoenzyme 1A1 (ALDH1A1) in various molecular subtypes of breast cancer","authors":"Ramya Suresh , Krishnappa Amita , Kalappa Prashantha , Hamse Kameshwar Vivek , Geethanjali Anil Kumar Burbure , Kanakapura Paramesh Hrushikesh","doi":"10.1016/j.senol.2025.100729","DOIUrl":"10.1016/j.senol.2025.100729","url":null,"abstract":"<div><h3>Background</h3><div>Cancer stem cells (CSCs) are a subpopulation of cancer cells implicated in tumor proliferation and progression. Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cytosolic isoenzyme that oxidizes intracellular aldehydes and is critical for normal and tumor stem cell differentiation. The aim of this study was to determine the expression of CSC marker, ALDH1A1, and its prognostic potential in invasive breast carcinoma.</div></div><div><h3>Methods</h3><div>This was a diagnostic analytical study involving 50 cases of invasive breast carcinoma who underwent mastectomy from January 2021 up to June 2022. The tumors were classified into their histological and molecular subtypes by assessing ER, PR, Her2 and Ki67. ALDH1 expression was studied, scored and correlated with known clinicopathological parameters.</div></div><div><h3>Results</h3><div>Out of 50 tumors, 28 tumors (56%) showed ALDH1 positivity. ALDH1 expression was significantly associated with ER/PR overexpression and Her-2 negativity. No significant association was noted between ALDH1A1 and other clinicopathological parameters.</div></div><div><h3>Conclusion</h3><div>This study observed a high prevalence of ALDH1A1 positivity in invasive breast carcinoma. ALDH1 expression was significantly associated with ER/PR overexpression and HER-2 negativity. Assessment of ALDH1A1 expression might help identify a high-risk subgroup of breast cancers and favor the use of ALDH as an independent prognostic marker. <em>In-silico</em> analysis reveals that HER2 and PR with ALDH1A1 bind very tightly.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100729"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146189374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hormone receptor (HR)- and HER2-dependent expression of hypoxia genes (HIF1A, HIF2A and HIF3A) at the transcriptional level in clinical breast tumor samples 临床乳腺肿瘤样本中缺氧基因（HIF1A、HIF2A和HIF3A）在转录水平上的激素受体（HR）和her2依赖性表达

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2026-01-01 Epub Date: 2026-02-19 DOI: 10.1016/j.senol.2026.100745

Berke Can Acar, Caglar Berkel

引用次数: 0

Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives 抗血管生成药物和多腺苷二磷酸核糖聚合酶（PARP）抑制剂在乳腺癌中的治疗意义：现状和未来展望

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-10-01 Epub Date: 2025-06-26 DOI: 10.1016/j.senol.2024.100658

Muhammad Adil , Ghazanfar Abbas , Mavara Iqbal , Sarmad Rasheed , Shamsa Kanwal

{"title":"Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives","authors":"Muhammad Adil , Ghazanfar Abbas , Mavara Iqbal , Sarmad Rasheed , Shamsa Kanwal","doi":"10.1016/j.senol.2024.100658","DOIUrl":"10.1016/j.senol.2024.100658","url":null,"abstract":"<div><div>Angiogenesis exhibits an integral role in cancer development and metastasis, therefore, antiangiogenic therapy forms the basis of several promising treatment strategies for breast cancer. Moreover, DNA damage has long been exploited in cancer chemotherapy and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors constitute a novel group of drugs for the targeted disruption of DNA repair phenomenon attributed to breast cancer. Several antiangiogenic drugs and PARP inhibitors are effectively used as sole agents for the therapeutic management of early breast cancer and breast cancer gene mutation–induced breast cancer, respectively. Whereas, other antiangiogenic agents are employed for the ancillary therapy of metastatic breast cancer in conjunction with chemotherapeutic drugs. Likewise, some PARP inhibitors are recommended as adjuncts to chemotherapy against the triple-negative form of breast cancer. Combinations of PARP inhibitors with immunotherapy have also demonstrated favorable outcomes and offer an efficient treatment strategy for breast cancer. Currently, the combinations of antiangiogenic agents and PARP inhibitors are under investigation for prospective synergistic or additive effects in breast cancer. Despite being suggested for high-risk patients, the prophylactic use of PARP inhibitors has not been supported by means of preclinical or clinical studies. Finally, the identification of patient cohorts, determination of predictive biomarkers, optimization of dosing strategies, validation of long-term safety, and containment of resistance issues, necessitate proper attention for improving the clinical efficacy of potentially useful antiangiogenic agents and PARP inhibitors against breast cancer.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100658"},"PeriodicalIF":0.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0